Skip to main content

01.12.2013 | Original Article

Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review

verfasst von: Eyup Sabri Ercan, Ulku Akyol Ardic, Burge Kabukcu Basay, Elif Ercan, Omer Basay

Erschienen in: ADHD Attention Deficit and Hyperactivity Disorders | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 1994, American Psychiatric Association) describes attention deficit hyperactivity disorder (ADHD) as a heterogeneous disorder; providing diagnostic criteria for three subtypes: hyperactive/impulsive (ADHD/HI), inattentive (ADHD/I), and combined type (ADHD/C). Differences among the subtypes are well defined, but there may be also differences in terms of treatment responses. The aim of this study is to assess the responses of ADHD/I and ADHD/C to atomoxetine treatment. The medical records of the January–June 2012 term, first time referrals to outpatient clinic, were reviewed, and 37 ADHD diagnosed primary school age children (18 ADHD/I, 19 ADHD/C) that were treated with atomoxetine were determined. Thirty-five of them who completed 8 weeks of treatment duration were recruited for the study. The children with an ADHD medication use history in 2 months time prior to onset of treatment and/or the children receiving additional psychopharmacologic treatment to atomoxetine were excluded. Baseline and eighth week assessment, records were evaluated. Efficacy assessments included Turgay DSM-IV ADHD Screening and Rating Scale parent and teacher forms (T-DSM-IV) and Clinical Global Impression Scale-Severity and Improvement subscales. Safety assessments included laboratory and body weight assessments, ECG, heart rate, and blood pressure evaluations (baseline and eighth week) along a scale filled by the parents at the eighth week to review side effects. Atomoxetine was found to be effective in both ADHD/I and ADHD/C groups. Atomoxetine also decreased the opposition defiance subscale scores of T-DSM-IV (both parent and teacher forms), whereas it was not found to make statistically significant difference in the conduct disorder subscale scores. Mean difference in 8-week time in T-DSM-IV hyperactivity subscale and total scores of parent and teacher forms; inattention subscale scores of only parent forms and the CGI- severity subscale scores; differed significantly among the ADHD/I and ADHD/C groups; that ADHD/C types responded better to medication. Results of this study revealed that atomoxetine is effective both in ADHD/I and ADHD/C subtypes. ADHD/C types may be responding better to atomoxetine treatment than the ADHD/I subtypes.
Literatur
Zurück zum Zitat AACAP (American Academy of Child and Adolescent Psychiatry) (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(7):894–921CrossRef AACAP (American Academy of Child and Adolescent Psychiatry) (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(7):894–921CrossRef
Zurück zum Zitat American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (1994).Washington (DC): American Psychiatric Association American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (1994).Washington (DC): American Psychiatric Association
Zurück zum Zitat Cheng JY, Chen RY, Ko JS, Ng EM (2007) Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology 194(2):197–209CrossRefPubMed Cheng JY, Chen RY, Ko JS, Ng EM (2007) Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology 194(2):197–209CrossRefPubMed
Zurück zum Zitat Derefinko KJ, Adams ZW, Milich R, Fillmore MT, Lorch EP, Lynam DR (2008) Response style differences in the inattentive and combined subtypes of attention-deficit/hyperactivity disorder. J Abnorm Child Psychol 36:745–758CrossRefPubMed Derefinko KJ, Adams ZW, Milich R, Fillmore MT, Lorch EP, Lynam DR (2008) Response style differences in the inattentive and combined subtypes of attention-deficit/hyperactivity disorder. J Abnorm Child Psychol 36:745–758CrossRefPubMed
Zurück zum Zitat Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD (2011) Time courses of improvement and symptom remission in children treated with atomoxetine for attentiondeficit/hyperactivity disorder: analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health 5:14. doi:10.1186/1753-2000-5-14 CrossRefPubMed Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD (2011) Time courses of improvement and symptom remission in children treated with atomoxetine for attentiondeficit/hyperactivity disorder: analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health 5:14. doi:10.​1186/​1753-2000-5-14 CrossRefPubMed
Zurück zum Zitat Ercan ES, Amado S, Somer O, Çıkoğlu S (2001) Development of a test battery for the assessment of attention deficit hyperactivity disorder [in Turkish]. Cocuk ve Genclik Ruh Saglığı Dergisi (J Child Adolesc Ment Health) 8:132–144 Ercan ES, Amado S, Somer O, Çıkoğlu S (2001) Development of a test battery for the assessment of attention deficit hyperactivity disorder [in Turkish]. Cocuk ve Genclik Ruh Saglığı Dergisi (J Child Adolesc Ment Health) 8:132–144
Zurück zum Zitat Gokler B, Unal F, Pehlivanturk B, Cengel Kultur E, Akdemir D, Taner Y (2004) Reliability and validity of schedule for affective disorders and schizophrenia for school-age children-present and lifetime version-Turkish version (K-SADS-PL-T) [in Turkish]. Cocuk ve Genclik Ruh Saglığı Dergisi (J Child Adolesc Ment Health) 11:3 Gokler B, Unal F, Pehlivanturk B, Cengel Kultur E, Akdemir D, Taner Y (2004) Reliability and validity of schedule for affective disorders and schizophrenia for school-age children-present and lifetime version-Turkish version (K-SADS-PL-T) [in Turkish]. Cocuk ve Genclik Ruh Saglığı Dergisi (J Child Adolesc Ment Health) 11:3
Zurück zum Zitat Guy W (1976) Clinical global impressions. ECDEU assessment manual for psychopharmacology, revised National Institute of Mental Health, Rockville, MD; 218–21 Guy W (1976) Clinical global impressions. ECDEU assessment manual for psychopharmacology, revised National Institute of Mental Health, Rockville, MD; 218–21
Zurück zum Zitat Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988CrossRefPubMed Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988CrossRefPubMed
Zurück zum Zitat Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ (2004) Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114:e1–e8CrossRefPubMed Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ (2004) Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114:e1–e8CrossRefPubMed
Zurück zum Zitat Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL (2008) Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2:25CrossRefPubMed Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL (2008) Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2:25CrossRefPubMed
Zurück zum Zitat Lahey BB, Pelham WE, Loney J, Lee SS, Willcutt E (2005) Instability of the DSM-IV subtypes of ADHD from preschool through elementary school. Arch Gen Psychiatry 62:896–902CrossRefPubMed Lahey BB, Pelham WE, Loney J, Lee SS, Willcutt E (2005) Instability of the DSM-IV subtypes of ADHD from preschool through elementary school. Arch Gen Psychiatry 62:896–902CrossRefPubMed
Zurück zum Zitat Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized placebo-controlled study. Am J Psychiatry 159:1896–1901CrossRefPubMed Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized placebo-controlled study. Am J Psychiatry 159:1896–1901CrossRefPubMed
Zurück zum Zitat Milich R, Balentine AC, Lynam DR (2001) ADHD combined type and ADHD predominantly inattentive type are distinct and unrelated disorders. Clin Psychol: Sci Pract 8:463–488CrossRef Milich R, Balentine AC, Lynam DR (2001) ADHD combined type and ADHD predominantly inattentive type are distinct and unrelated disorders. Clin Psychol: Sci Pract 8:463–488CrossRef
Zurück zum Zitat Pliszka SR, Crismon ML, Hughes CW et al (2006) The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642–657CrossRefPubMed Pliszka SR, Crismon ML, Hughes CW et al (2006) The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642–657CrossRefPubMed
Zurück zum Zitat Polanczyk G, Jensen P (2008) Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update. Child Adolesc Psychiatr Clin N Am 17(2):245–260CrossRefPubMed Polanczyk G, Jensen P (2008) Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update. Child Adolesc Psychiatr Clin N Am 17(2):245–260CrossRefPubMed
Zurück zum Zitat Solanto M, Newcorn J, Vail L, Gilbert S, Ivanov I, Lara R (2009) Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19(6):663–671CrossRefPubMed Solanto M, Newcorn J, Vail L, Gilbert S, Ivanov I, Lara R (2009) Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19(6):663–671CrossRefPubMed
Zurück zum Zitat Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ (2002) Results from 2 proof-of-concept, placebocontrolled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140–1147CrossRefPubMed Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ (2002) Results from 2 proof-of-concept, placebocontrolled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140–1147CrossRefPubMed
Zurück zum Zitat Steele M (2006) Introduction to remission in ADHD: raising the bar. Clin Ther 28:1879–1881CrossRef Steele M (2006) Introduction to remission in ADHD: raising the bar. Clin Ther 28:1879–1881CrossRef
Zurück zum Zitat Steele M, Jensen PS, Quinn DM (2006) Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther, 28:1892–1908 Steele M, Jensen PS, Quinn DM (2006) Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther, 28:1892–1908
Zurück zum Zitat Taylor E, Döpfner M, Sergeant J et al (2004) European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):17–30 Taylor E, Döpfner M, Sergeant J et al (2004) European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):17–30
Zurück zum Zitat Turgay A (1994) Disruptive behavior disorders child and adolescent screening and rating scales for children, adolescents, parents and teachers. West Bloomfield (Michigan), Integrative Therapy Institute Publication Turgay A (1994) Disruptive behavior disorders child and adolescent screening and rating scales for children, adolescents, parents and teachers. West Bloomfield (Michigan), Integrative Therapy Institute Publication
Zurück zum Zitat Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:647–655CrossRefPubMed Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:647–655CrossRefPubMed
Zurück zum Zitat Wilens T, Kratochvil C, Newcorn J, Gao H (2006) Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 45:149–157CrossRefPubMed Wilens T, Kratochvil C, Newcorn J, Gao H (2006) Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 45:149–157CrossRefPubMed
Metadaten
Titel
Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review
verfasst von
Eyup Sabri Ercan
Ulku Akyol Ardic
Burge Kabukcu Basay
Elif Ercan
Omer Basay
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
ADHD Attention Deficit and Hyperactivity Disorders / Ausgabe 4/2013
Print ISSN: 1866-6116
Elektronische ISSN: 1866-6647
DOI
https://doi.org/10.1007/s12402-013-0111-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.